Figure 6.

Treatment with LKAb reduces lupus-like disease in MRL-lpr mice. Mice (6–7/group) were injected intraperitoneally with LKAb or PBS (from the age of 6 wk until termination of the experiment at 20 wk) and followed for manifestations of disease. A) IgG2a anti-chromatin autoantibody levels determined by ELISA at 12 wk of age. B) Progression of lymphadenopathy between 12 and 16 wk of age assessed by palpation of axillary and salivary lymph nodes (LNs) and scored on a 0–4 scale. C) Kidney disease determined by histologic examination for GN at 20 wk of age. Representative images for treated and control mice are shown. D) Kaplan-Meier plot representing survival rates of treated and control mice. *P < 0.05, **P < 0.005, ***P < 0.0005, LKAb-treated vs. PBS control-treated mice; Student’s t test.